Author Interviews, Autism, Neurology / 11.12.2019
Genetic Lead Suggests Ketamine May Benefit Autism, Tourette’s and Schizophrenia
MedicalResearch.com Interview with:
Dr. Neil Dawson PhD
Senior Lecturer
Lancaster University
MedicalResearch.com: What is the background for this study?
Response: Deletions on chromosome 2p16.3, involving deletion of the NEUREXIN1 gene, dramatically increase the risk of developing a wide range of neurodevelopmental disorders including autism, Tourette’s syndrome and schizophrenia. We don’t fully understand the mechanisms involved. In our study we wanted to understand how the genetic deletion impacts on brain function and the ability of brain regions to communicate with one another, as these are known to be impaired in these neurodevelopmental disorders. We also wanted to determine how the genetic deletion impacts on the function of neurotransmitter systems involved in these disorders, and whether drugs targeting these neurotransmitter systems could restore some of the deficits in brain function seen.
(more…)